VBWG
Slides

Core Curriculum

• Impact of vascular biology in treatment of cardiovascular disease Section I: RAAS manipulation

The VBWG Core Curriculum 2003 slide lecture compendium, Impact of vascular biology in treatment of cardiovascular disease, provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Areas of focus:

The slides and accompanying notes in this section address modulation of the reninangiotensin- aldosterone system (RAAS) and new data that solidify its role in secondary prevention. In particular, there is particular focus on the "peri-interventional" period-the time immediately prior to and following hospital discharge-and on the evidence supporting rigorous adherence to multifactorial risk reduction regimens.



03RASS001.pdf (0.4MB)03RASS001.pdf (0.4MB)

A. Epidemiology Update

Download 03RASS001.ppt (4 slides - 0.9MB)

A.  Epidemiology Update Nationwide epidemic of obesity Obesity accelerates coronary atherosclerosis in men CV disease: Patients at risk

B. Cell wall triggers for CV disease

Download 03RASS002.ppt (12 slides - 2.2MB)

B.  Cell wall triggers for CV disease Role of visceral obesity in platelet activation The RAAS and vascular inflammation Ang II, oxidative stress, and acute ischemic events Cytokines regulate plaque development and rupture Increased NAD(P)H oxidase activity in unstable vs stable CAD Ang II regulates NAD(P)H oxidase expression Colocalization of ACE and LDL in aortic valvular lesions ACE inhibition reduces macrophage uptake of oxLDL ACE inhibition blunts post-CABG IL-6 release ACE inhibition increases tPA release through endogenous bradykinin Sustained decrease in PAI-1 antigen over time with ACE inhibition

C. Clinical trial update:

Download 03RASS003.ppt (28 slides - 5.3MB)

C.  Clinical trial update:  ALLHAT: Design ALLHAT: BP reduction by treatment group ALLHAT: Fatal CHD or nonfatal MI ALLHAT: Treatment effects on glucose metabolism ANBP2: Design ANBP2: BP reduction by treatment group ANBP2: Treatment effects on CV events and all-cause death Lessons from ALLHAT and ANBP2 LIFE: Study design LIFE: Primary outcome (CV death, MI, stroke) LIFE: Effects of ARB on death, stroke, and MI HOPE: Stroke reduction independent of BP reduction HOPE: Stroke reduction consistent with regard to baseline conditions HOPE: Stroke reduction consistent with regard to baseline medications MITRA PLUS: Benefits of ACE inhibition on post-MI survival MITRA PLUS: Differences among ACE inhibitors in acute MI – ’ HOPE: Reduction in primary outcome among women and men HOPE: Prevention of heart failure with ramipril OPTIMAAL: Effects of AT1 receptor blockade and ACE inhibition in CDC/AHA statement on CRP measurement: CDC/AHA statement on CRP measurement: Optimal therapy for the peri-interventional patient Quality of care and in-hospital outcome Peripheral vascular disease: Missed opportunity for CV intervention Beneficial effects on compliance of the Cardiac Hospitalization Atherosclerosis Improving perioperative care: Materials available through the GAP program  of the ACC

D. Diabetes and the peri-interventional patient

Download 03RASS004.ppt (12 slides - 2.4MB)

D.  Diabetes and the peri-interventional patient ’ Diabetes complications: Proposed role of advanced glycation end products (AGEs) ACE inhibition blunts serum accumulation of AGEs ACE inhibition enhances glucose uptake in skeletal muscle by a bradykinin-mediated mechanism LIFE: Effects of ARB on death, stroke, and MI Steno-2: Effects of multifactorial intervention on macrovascular and microvascular outcomes ADA recommendations 2003: ACE inhibitors ACC/AHA 2002 guideline update for the management of patients with chronic stable angina ADA recommendations 2003: Aspirin ADA recommendations 2003: Treatment goals Proposed algorithm for treatment of hypertension in diabetes
corerefs.pdf (0.0MB)corerefs.pdf (0.0MB)
Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine.

The editorial content of this program does not necessarily reflect the views or recommendations of the University of Florida College of Medicine or AstraZeneca, Aventis Pharmaceuticals Inc, King Pharmaceuticals, Pfizer Inc, Wyeth Pharmaceuticals, or the publisher. The reader is advised to consult the full prescribing information of each product prior to use.

This program was prepared and produced by Medical Education Consultants, Inc, Westport, Connecticut, on behalf of the University of Florida College of Medicine through an unrestricted educational grant provided by AstraZeneca, Aventis Pharmaceuticals Inc, King Pharmaceuticals, Pfizer Inc, and Wyeth Pharmaceuticals.

©2003 Medical Education Consultants, Inc. (MEDCON). All rights reserved.

biologycardiovascularcompendiumCurriculummanipulationRAASvascularVBWG

Related at vwbg.org

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV - Update: RAAS manipulation and cardiovascular risk--Hope for Peace?

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section IV: RAAS manipulation and cardiovascular risk

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section V: Atrial fibrillation, anticoagulation, and stroke prevention

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.
More related